[UFTPM (UFT + CDDP + MMC) therapy for progressive stomach cancer. Research Association of Progressive Stomach Cancer].
We organized a cooperative research group consisting of 10 institutions and UFTPM therapy was given patients with unresectable and postoperatively relapsed stomach cancer. As the result, 20 cases were registered and the ratio of PR according to the criteria of stomach cancer chemotherapy was 4 out of 17 complete cases (23.5%), excluding 3 incomplete cases. The efficacy for the cases treated with more than 2 courses was 36.4% (4/11) and that for cases with 3 courses was 75% (3/4). One case with 3 courses was resectable and the cancer cells disappeared. Adverse effects of grade 3 or more according to the WHO criteria were observed in 20% of the cases.
Iwazaki
R
R
Dept. of Gastroenterology, Juntendo University School of Medicine.
Yasutake
K
K
Fukuyama
Y
Y
Hasegawa
K
K
Koizumi
W
W
Sasai
T
T
Kurihara
M
M
Kubo
Y
Y
Ishikawa
K
K
Hayakawa
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D002945:Cisplatin